Exagen (NASDAQ:XGN) PT Lowered to $7.00
Exagen (NASDAQ:XGN) PT Lowered to $7.00
Exagen (NASDAQ:XGN – Get Rating) had its price target lowered by analysts at Canaccord Genuity Group from $8.00 to $7.00 in a research note issued on Tuesday, The Fly reports. The firm presently has a "buy" rating on the stock. Canaccord Genuity Group's price objective suggests a potential upside of 105.88% from the stock's previous close.
A number of other equities research analysts have also recently issued reports on XGN. KeyCorp cut shares of Exagen from an "overweight" rating to a "sector weight" rating in a research note on Friday, August 5th. Canaccord Genuity Group dropped their price target on shares of Exagen from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Exagen has an average rating of "Moderate Buy" and a consensus price target of $11.75.
Get Exagen alerts:Exagen Price Performance
Shares of NASDAQ XGN opened at $3.40 on Tuesday. The stock has a market capitalization of $55.28 million, a price-to-earnings ratio of -1.50 and a beta of 1.17. Exagen has a 12 month low of $2.10 and a 12 month high of $12.89. The firm's 50 day simple moving average is $2.98 and its 200-day simple moving average is $4.83. The company has a debt-to-equity ratio of 0.43, a current ratio of 9.30 and a quick ratio of 9.30.
Institutional Trading of Exagen
Institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. purchased a new stake in Exagen in the 1st quarter valued at about $27,000. Intrust Bank NA purchased a new stake in Exagen during the second quarter worth about $57,000. First Bank & Trust increased its stake in Exagen by 47.1% during the second quarter. First Bank & Trust now owns 23,176 shares of the company's stock worth $133,000 after purchasing an additional 7,423 shares during the period. Advisors Capital Management LLC increased its stake in Exagen by 66.2% during the third quarter. Advisors Capital Management LLC now owns 67,923 shares of the company's stock worth $143,000 after purchasing an additional 27,050 shares during the period. Finally, Envestnet Asset Management Inc. increased its stake in Exagen by 7.7% during the first quarter. Envestnet Asset Management Inc. now owns 25,731 shares of the company's stock worth $207,000 after purchasing an additional 1,839 shares during the period. 65.94% of the stock is currently owned by hedge funds and other institutional investors.About Exagen
(Get Rating)
Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Read More
- Get a free copy of the StockNews.com research report on Exagen (XGN)
- Use The Airbnb Stock Implosion to Your Advantage
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- International Game Technology is Well Worth the Gamble
- Why Lowe's Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
據The Fly報道,在週二發佈的一份研究報告中,Canaccel Genuity Group的分析師將埃克森美孚(納斯達克:XGN-GET評級)的目標價從8.00美元下調至7.00美元。該公司目前對該股的評級為“買入”。Canaccel Genuity Group的目標價顯示,該股較前一交易日收盤價有105.88%的潛在上漲空間。
其他一些股票研究分析師最近也發佈了關於XGN的報告。KeyCorp在8月5日星期五的一份研究報告中將Exagen的股票評級從“增持”下調至“行業權重”。週二,Canaccel Genuity Group將Exagen的目標價從8.00美元下調至7.00美元,並在一份研究報告中對該股設定了“買入”評級。一位股票研究分析師對該股的評級為持有,四位分析師對該股的評級為買入。根據MarketBeat的資料,Exagen的平均評級為“中等買入”,共識目標價為11.75美元.
到達埃克森警報:Exagen性價比
週二,納斯達克XGN的股價開盤報3.4美元。該股市值為5,528萬美元,市盈率為-1.5倍,貝塔係數為1.17。Exagen的12個月低點為2.10美元,12個月高位為12.89美元。該公司的50日簡單移動均線切入位為2.98美元,200日簡單移動均線切入位為4.83美元。該公司的債務權益比為0.43,流動比率為9.30,速動比率為9.30。
Exagen的制度性交易
機構投資者和對衝基金最近買賣了該股的股票。羅素投資集團有限公司(Russell Investments Group Ltd.)在第一季度購買了Exagen的新股份,價值約2.7萬美元。InTrust Bank NA在第二季度購買了Exagen的新股份,價值約5.7萬美元。First Bank&Trust在第二季度增持了47.1%的Exagen股份。First Bank&Trust在此期間又購買了7,423股,現在擁有23,176股該公司股票,價值13.3萬美元。Advisors Capital Management LLC在第三季度增持了Exagen 66.2%的股份。Advisors Capital Management LLC在此期間額外購買了27,050股,現在擁有67,923股該公司股票,價值143,000美元。最後,Envestnet Asset Management Inc.在第一季度將其在Exagen的持股增加了7.7%。Envestnet Asset Management Inc.在此期間又購買了1,839股,現在擁有25,731股該公司股票,價值20.7萬美元。65.94%的股票目前由對衝基金和其他機構投資者持有。關於艾克森
(獲取評級)
Exagen Inc.在美國開發和銷售基於其細胞結合補體激活產品技術的各種測試產品,品牌為AVISE。它使風濕科醫生能夠通過自身免疫和自身免疫相關疾病的診斷、預後和監測來護理患者,包括系統性紅斑狼瘡(SLE)和類風濕性關節炎(RA)。
閲讀更多內容
- 免費獲取StockNews.com關於Exagen的研究報告(XGN)
- 利用愛彼迎股票的內爆對你有利
- 提供高股息收益的3只天然氣股票
- 國際遊戲技術值得賭一把
- 為什麼Lowe‘s上升,Home Depot下降
- TJX公司可能突破新高
接受《Exagen Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Exagen和相關公司的最新新聞和分析師評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧